Kling Biotherapeutics appoints Dr. med. Michael Koslowski as Chief Executive Officer

AMSTERDAM, December 12, 2022 /PRNewswire/ — Kling Biotherapeutics, BV, a clinical company pioneering the discovery and development of novel antibody-based therapeutics, today announced the appointment of Michael Koslowski, MD as chief executive officer. dr. Koslowski will oversee Kling’s growing team of experienced drug developers and its portfolio of breakthrough programs in oncology and infectious diseases.

dr. Koslowski joins Kling from GammaDelta Therapeutics, where he served as Head of Research and Development and Chief Medical Officer until the company’s successful acquisition by Takeda Pharmaceuticals in 2022. In this role, Michael led the preclinical and clinical development of allogeneic cancer cell therapies, building on two decades of experience in the development of new drugs. Prior to GammaDelta, Dr. Koslowski held senior positions at Mission Therapeutics, Glenmark Pharmaceuticals, and Boehringer Ingelheim. In addition, he was a founding member and head of novel target and antibody development at Ganymed Pharmaceuticals, a German biotech company acquired by Astellas in 2016. Michael’s industry experience followed an academic career in experimental and translational oncology at the University of Mainz, where he also obtained a habilitation degree after a doctorate at Saarland University and a medical degree at the University of Cologne.

“Michael brings to Kling a proven track record of developing cutting-edge drugs using a variety of new technologies,” he said Timothy M. Wright, MD, president of the board of the Kling company. “He is uniquely qualified to advance Kling’s deep pipeline of antibody-based medicines, including our first-in-class anti-CD9 antibody, KBA1412, which holds great promise for a range of solid tumor patients. Few executives have the scientific, medical, and commercial depth that Michael brings to this company.”

dr. Koslowski sees Kling’s platform as a rule changer for discovering new oncology targets and therapeutics: “I am very excited to join and lead Kling at this early stage of the company’s development. Kling’s proprietary world-class platform technology represents an extraordinary opportunity to identify and develop new breakthrough therapies for the benefit of cancer patients,” he said. “We have within reach the potential to revolutionize the field of cancer immunotherapy.”

About Kling Biotherapeutics

Kling Biotherapeutics is Amsterdam, a Dutch clinical-stage biotech company that has developed a robust array based on the assessment of B cells present in individuals with outstanding responses to cancer and infectious diseases. Its proprietary B cell immortalization platform enables rapid functional antibody screening and has led to the identification of several antibodies with solid tumor and leukemia cytotoxicity targeting novel protein epitopes (cancer and infectious diseases) and newly discovered cancer-specific membrane post-translational modifications.

CONTACT: [email protected]

SOURCE Kling Biotherapeutics, BV

Leave a Comment

Your email address will not be published. Required fields are marked *